Cite

HARVARD Citation

    Zeissig, S. et al. (2019). Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease. Gut. 68 (1), pp. 25-39. [Online]. 
  
Back to record